Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Peter L Anderson

Showing results (111-120 of 271) with videos related to

Pageof 28
Sort By:
Journal of Pharmaceutical and Biomedical Analysis|February 2, 2016
Application of an intracellular assay for determination of tenofovir-diphosphate and emtricitabine-triphosphate from erythrocytes using dried blood spotsJia-Hua Zheng, Caitlin Rower, Kevin McAllister, et al.
AIDS and Behavior|September 28, 2023
The Effect of Disclosure of PrEP Use on Adherence Among African Young Women in an Open-Label PrEP Study: Findings from HPTN 082Geetha Beauchamp, Sybil Hosek, Deborah Donnell, et al.
Sexually Transmitted Infections|May 31, 2023
Determinants of adherence to daily PrEP measured as intracellular tenofovir diphosphate concentrations over 24 months of follow-up among men who have sex with menMark Am van den Elshout, Elske Hoornenborg, Liza Coyer, et al.
BMC Women'S Health|May 19, 2023
Trust in the provider and accurate self-reported PrEP adherence among adolescent girls and young women in South Africa and Zimbabwe: HPTN 082 studyGeetha Beauchamp, Deborah Donnell, Sybil Hosek, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|February 8, 2018
Metabolic Effects of Preexposure Prophylaxis With Coformulated Tenofovir Disoproxil Fumarate and EmtricitabineDavid V Glidden, Kathleen Mulligan, Vanessa McMahan, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|August 9, 2020
Sex Hormone Therapy and Tenofovir Diphosphate Concentration in Dried Blood Spots: Primary Results of the Interactions Between Antiretrovirals And Transgender Hormones StudyRobert M Grant, Marion Pellegrini, Patricia A Defechereux, et al.
AIDS Research and Human Retroviruses|July 11, 2022
Gender-Affirming Hormone Pharmacokinetics Among Adolescent and Young Adult Transgender Persons Receiving Daily Emtricitabine/Tenofovir Disoproxil FumarateJenna Yager, Kristina M Brooks, Jennifer Brothers, et al.
Clinical Pharmacology and Therapeutics|June 9, 2018
CYP2D6 Genotype Phenotype Discordance Due to Drug-Drug InteractionAndrew A Monte, Kelsey West, Kyle T McDaniel, et al.
The Journal of Infectious Diseases|April 22, 2015
Strong Correlation Between Concentrations of Tenofovir (TFV) Emtricitabine (FTC) in Hair and TFV Diphosphate and FTC Triphosphate in Dried Blood Spots in the iPrEx Open Label Extension: Implications for Pre-exposure Prophylaxis Adherence MonitoringMonica Gandhi, David V Glidden, Albert Liu, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|June 23, 2017
Brief Report: Recovery of Bone Mineral Density After Discontinuation of Tenofovir-Based HIV Pre-exposure ProphylaxisDavid V Glidden, Kathleen Mulligan, Vanessa McMahan, et al.
Pageof 28

Showing results (111-120 of 271) with videos related to

Sort By:
Pageof 28
Journal of Pharmaceutical and Biomedical Analysis|February 2, 2016
Application of an intracellular assay for determination of tenofovir-diphosphate and emtricitabine-triphosphate from erythrocytes using dried blood spotsJia-Hua Zheng, Caitlin Rower, Kevin McAllister, et al.
AIDS and Behavior|September 28, 2023
The Effect of Disclosure of PrEP Use on Adherence Among African Young Women in an Open-Label PrEP Study: Findings from HPTN 082Geetha Beauchamp, Sybil Hosek, Deborah Donnell, et al.
Sexually Transmitted Infections|May 31, 2023
Determinants of adherence to daily PrEP measured as intracellular tenofovir diphosphate concentrations over 24 months of follow-up among men who have sex with menMark Am van den Elshout, Elske Hoornenborg, Liza Coyer, et al.
BMC Women'S Health|May 19, 2023
Trust in the provider and accurate self-reported PrEP adherence among adolescent girls and young women in South Africa and Zimbabwe: HPTN 082 studyGeetha Beauchamp, Deborah Donnell, Sybil Hosek, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|February 8, 2018
Metabolic Effects of Preexposure Prophylaxis With Coformulated Tenofovir Disoproxil Fumarate and EmtricitabineDavid V Glidden, Kathleen Mulligan, Vanessa McMahan, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|August 9, 2020
Sex Hormone Therapy and Tenofovir Diphosphate Concentration in Dried Blood Spots: Primary Results of the Interactions Between Antiretrovirals And Transgender Hormones StudyRobert M Grant, Marion Pellegrini, Patricia A Defechereux, et al.
AIDS Research and Human Retroviruses|July 11, 2022
Gender-Affirming Hormone Pharmacokinetics Among Adolescent and Young Adult Transgender Persons Receiving Daily Emtricitabine/Tenofovir Disoproxil FumarateJenna Yager, Kristina M Brooks, Jennifer Brothers, et al.
Clinical Pharmacology and Therapeutics|June 9, 2018
CYP2D6 Genotype Phenotype Discordance Due to Drug-Drug InteractionAndrew A Monte, Kelsey West, Kyle T McDaniel, et al.
The Journal of Infectious Diseases|April 22, 2015
Strong Correlation Between Concentrations of Tenofovir (TFV) Emtricitabine (FTC) in Hair and TFV Diphosphate and FTC Triphosphate in Dried Blood Spots in the iPrEx Open Label Extension: Implications for Pre-exposure Prophylaxis Adherence MonitoringMonica Gandhi, David V Glidden, Albert Liu, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|June 23, 2017
Brief Report: Recovery of Bone Mineral Density After Discontinuation of Tenofovir-Based HIV Pre-exposure ProphylaxisDavid V Glidden, Kathleen Mulligan, Vanessa McMahan, et al.
Pageof 28